Literature DB >> 17143722

Molecular characterization of a reassortant virus derived from Lassa and Mopeia viruses.

Dmitry A Moshkoff1, Maria S Salvato, Igor S Lukashevich.   

Abstract

In this article we describe two new complete genomic sequences of Old World Arenaviruses: the Mopeia (MOP) virus and the reassortant MOP/LAS virus, clone 29, or ML29. This reassortant has the large (L) RNA from MOP virus and the small (S) RNA from Lassa (LAS) virus, Josiah strain. Recent studies showed that the ML29 virus is not pathogenic for mice, guinea pigs, or macaques, can completely protect guinea pigs from Lassa virus, and elicit vigorous cell-mediated immunity in immunized monkeys (Lukashevich, I. S., Patterson, J., Carrion, R., Moshkoff, D., Ticer, A., Zapata, J., Brasky, K., Geiger, R., Hubbard, G. B., Bryant, J., and Salvato, M. S., J Virol 79, 13934-13942, 2005). This is a molecular characterization of a reassortant virus, which has been put forward as a live attenuated vaccine candidate against Lassa Fever. Sequence analysis of this reassortant virus revealed 5 non-conservative amino acid substitutions that distinguished it from the parental LAS and MOP viruses. Three substitutions were found outside the conserved RNA-dependent RNA polymerase (RdRp) motifs. A fourth substitution was located between the glycoprotein (GPC)-cleavage site and the putative fusion peptide of GP2. The nucleocapsid protein (NP) contained a fifth substitution in the carboxyl-terminal region of the protein. Two mutations were found within each non-coding terminus of the L segment and one mutation was located in the 3' non-coding region of the S segment of the MOP/LAS virus. ML29 mutations in its genomic termini may have implications for the genetic stability and replication efficiency of ML29 reassortant.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17143722      PMCID: PMC1892610          DOI: 10.1007/s11262-006-0050-3

Source DB:  PubMed          Journal:  Virus Genes        ISSN: 0920-8569            Impact factor:   2.332


  19 in total

1.  Completion of the Lassa fever virus sequence and identification of a RING finger open reading frame at the L RNA 5' End.

Authors:  M Djavani; I S Lukashevich; A Sanchez; S T Nichol; M S Salvato
Journal:  Virology       Date:  1997-09-01       Impact factor: 3.616

2.  Isolation of an arenavirus closely related to Lassa virus from Mastomys natalensis in south-east Africa.

Authors:  H Wulff; B M McIntosh; D B Hamner; K M Johnson
Journal:  Bull World Health Organ       Date:  1977       Impact factor: 9.408

3.  Protection of rhesus monkeys from fatal Lassa fever by vaccination with a recombinant vaccinia virus containing the Lassa virus glycoprotein gene.

Authors:  S P Fisher-Hoch; J B McCormick; D Auperin; B G Brown; M Castor; G Perez; S Ruo; A Conaty; L Brammer; S Bauer
Journal:  Proc Natl Acad Sci U S A       Date:  1989-01       Impact factor: 11.205

4.  A live attenuated vaccine for Lassa fever made by reassortment of Lassa and Mopeia viruses.

Authors:  Igor S Lukashevich; Jean Patterson; Ricardo Carrion; Dmitry Moshkoff; Anysha Ticer; Juan Zapata; Kathleen Brasky; Robert Geiger; Gene B Hubbard; Joseph Bryant; Maria S Salvato
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

5.  Nucleotide sequence of the Lassa virus (Josiah strain) S genome RNA and amino acid sequence comparison of the N and GPC proteins to other arenaviruses.

Authors:  D D Auperin; J B McCormick
Journal:  Virology       Date:  1989-02       Impact factor: 3.616

6.  Experimental infection of rhesus monkeys with Lassa virus and a closely related arenavirus, Mozambique virus.

Authors:  D H Walker; K M Johnson; J V Lange; J J Gardner; M P Kiley; J B McCormick
Journal:  J Infect Dis       Date:  1982-09       Impact factor: 5.226

Review 7.  Phylogeny and evolution of old world arenaviruses.

Authors:  Sébastien Emonet; Jean-Jacques Lemasson; Jean-Paul Gonzalez; Xavier de Lamballerie; Rémi N Charrel
Journal:  Virology       Date:  2006-02-21       Impact factor: 3.616

8.  Sequence analysis of the S RNA of the African arenavirus Mopeia: an unusual secondary structure feature in the intergenic region.

Authors:  S M Wilson; J C Clegg
Journal:  Virology       Date:  1991-02       Impact factor: 3.616

9.  Recovery of a Lassa-related arenavirus in Zimbabwe.

Authors:  K M Johnson; P Taylor; L H Elliott; O Tomori
Journal:  Am J Trop Med Hyg       Date:  1981-11       Impact factor: 2.345

10.  Gene mapping in Pichinde virus: assignment of viral polypeptides to genomic L and S RNAs.

Authors:  D G Harnish; K Dimock; D H Bishop; W E Rawls
Journal:  J Virol       Date:  1983-05       Impact factor: 5.103

View more
  18 in total

1.  Safety, immunogenicity, and efficacy of the ML29 reassortant vaccine for Lassa fever in small non-human primates.

Authors:  Igor S Lukashevich; Ricardo Carrion; Maria S Salvato; Keith Mansfield; Kathleen Brasky; Juan Zapata; Cristiana Cairo; Marco Goicochea; Gia E Hoosien; Anysha Ticer; Joseph Bryant; Harry Davis; Rasha Hammamieh; Maria Mayda; Marti Jett; Jean Patterson
Journal:  Vaccine       Date:  2008-08-08       Impact factor: 3.641

2.  Genetic variation in vitro and in vivo of an attenuated Lassa vaccine candidate.

Authors:  Juan C Zapata; Marco Goicochea; Yuka Nadai; Lindsay M Eyzaguirre; Jean K Carr; Luke J Tallon; Lisa Sadzewicz; Garry Myers; Claire M Fraser; Qi Su; Mahmoud Djavani; Igor S Lukashevich; Maria S Salvato
Journal:  J Virol       Date:  2013-12-11       Impact factor: 5.103

3.  Genomic profiling of host responses to Lassa virus: therapeutic potential from primate to man.

Authors:  Juan C Zapata; Maria S Salvato
Journal:  Future Virol       Date:  2015-03-13       Impact factor: 1.831

Review 4.  Lymphocytic choriomeningitis virus (LCMV) infection of macaques: a model for Lassa fever.

Authors:  Juan C Zapata; C David Pauza; Mahmoud M Djavani; Juan D Rodas; Dmitry Moshkoff; Joseph Bryant; Eugene Ateh; Cybele Garcia; Igor S Lukashevich; Maria S Salvato
Journal:  Antiviral Res       Date:  2011-07-27       Impact factor: 5.970

5.  Pre-clinical development of a vaccine against Lassa fever.

Authors:  L Banadyga; D R Stein; X Qiu; D Safronetz
Journal:  Can Commun Dis Rep       Date:  2018-06-07

6.  Vaccine Platforms to Control Arenaviral Hemorrhagic Fevers.

Authors:  Ricardo Carrion; Peter Bredenbeek; Xiaohong Jiang; Irina Tretyakova; Peter Pushko; Igor S Lukashevich
Journal:  J Vaccines Vaccin       Date:  2012-11-20

7.  A ML29 reassortant virus protects guinea pigs against a distantly related Nigerian strain of Lassa virus and can provide sterilizing immunity.

Authors:  Ricardo Carrion; Jean L Patterson; Curtis Johnson; Monica Gonzales; Carmen R Moreira; Anysha Ticer; Kathleen Brasky; Gene B Hubbard; Dmitry Moshkoff; Juan Zapata; Maria S Salvato; Igor S Lukashevich
Journal:  Vaccine       Date:  2007-02-27       Impact factor: 3.641

Review 8.  Vaccination strategies against highly pathogenic arenaviruses: the next steps toward clinical trials.

Authors:  Stephan Olschläger; Lukas Flatz
Journal:  PLoS Pathog       Date:  2013-04-11       Impact factor: 6.823

Review 9.  Arenavirus variations due to host-specific adaptation.

Authors:  Juan C Zapata; Maria S Salvato
Journal:  Viruses       Date:  2013-01-17       Impact factor: 5.048

Review 10.  Advanced vaccine candidates for Lassa fever.

Authors:  Igor S Lukashevich
Journal:  Viruses       Date:  2012-10-29       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.